Normal view

Received — 2 April 2026 ⏭

Omics In Lung
Pathogenesis and immune regulation of rheumatoid arthritis-associated interstitial lung disease: from basic research to clinical implications Yaxin Cheng · Yu Shan · Yixin Zheng · Fuyu Zhao · Yiming Shi · Chenyang Song · Yunshen Li · Jianan Zhao · Cen Chang · Yuguang Wang · Dongyi He
Front Immunol. 2026 Mar 13;17:1770348. doi: 10.3389/fimmu.2026.1770348. eCollection 2026.ABSTRACTInterstitial lung disease (ILD) is one of the most common extra-articular manifestations of rheumatoid arthritis (RA). Some patients with RA-ILD may develop progressive pulmonary fibrosis, leading to severe impairment of lung function and respiratory failure, which impacts quality of life and can even be life-threatening. This review identified genetic susceptibility, environmental factors, and immun
30 March 2026 at 18:00

Pathogenesis and immune regulation of rheumatoid arthritis-associated interstitial lung disease: from basic research to clinical implications

By: Yaxin Cheng · Yu Shan · Yixin Zheng · Fuyu Zhao · Yiming Shi · Chenyang Song · Yunshen Li · Jianan Zhao · Cen Chang · Yuguang Wang · Dongyi He

30 March 2026 at 18:00

Front Immunol. 2026 Mar 13;17:1770348. doi: 10.3389/fimmu.2026.1770348. eCollection 2026.

ABSTRACT

Interstitial lung disease (ILD) is one of the most common extra-articular manifestations of rheumatoid arthritis (RA). Some patients with RA-ILD may develop progressive pulmonary fibrosis, leading to severe impairment of lung function and respiratory failure, which impacts quality of life and can even be life-threatening. This review identified genetic susceptibility, environmental factors, and immune dysregulation as key contributors to the etiology and pathogenesis of RA-ILD. We highlight that autoantibodies, adaptive immune abnormalities, and tertiary lymphoid organ formation significantly drive pulmonary inflammation and fibrosis, while pro-inflammatory cytokines and epithelial-mesenchymal transition (EMT) further contribute to lung tissue injury. Current treatment options, including glucocorticoids, immunosuppressants, and antifibrotic agents such as nintedanib and pirfenidone, are often limited by substantial side effects. Additionally, emerging therapies like JAK inhibitors, CAR-T cells, and the upcoming phosphodiesterase-4B inhibitor, nerandomilast, show promise, but no curative treatment exists to date. Future research could focus on multi-omics technologies and conducting multicenter clinical trials to establish therapeutic targets and advance precision medicine for RA-ILD.

PMID:41909710 | PMC:PMC13021622 | DOI:10.3389/fimmu.2026.1770348

Received — 25 February 2026 ⏭

cs.AI, q-bio.NC updates on arXiv.org
AttestLLM: Efficient Attestation Framework for Billion-scale On-device LLMs Ruisi Zhang · Yifei Zhao · Neusha Javidnia · Mengxin Zheng · Farinaz Koushanfar
arXiv:2509.06326v2 Announce Type: replace-cross Abstract: As on-device LLMs(e.g., Apple on-device Intelligence) are widely adopted to reduce network dependency, improve privacy, and enhance responsiveness, verifying the legitimacy of models running on local devices becomes critical. Existing attestation techniques are not suitable for billion-parameter Large Language Models (LLMs), struggling to remain both time- and memory-efficient while addressing emerging threats in the LLM era. In this pap
24 February 2026 at 13:00

AttestLLM: Efficient Attestation Framework for Billion-scale On-device LLMs

cs.AI, q-bio.NC updates on arXiv.org

By: Ruisi Zhang · Yifei Zhao · Neusha Javidnia · Mengxin Zheng · Farinaz Koushanfar

24 February 2026 at 13:00

arXiv:2509.06326v2 Announce Type: replace-cross Abstract: As on-device LLMs(e.g., Apple on-device Intelligence) are widely adopted to reduce network dependency, improve privacy, and enhance responsiveness, verifying the legitimacy of models running on local devices becomes critical. Existing attestation techniques are not suitable for billion-parameter Large Language Models (LLMs), struggling to remain both time- and memory-efficient while addressing emerging threats in the LLM era. In this paper, we present AttestLLM, the first-of-its-kind attestation framework to protect the hardware-level intellectual property (IP) of device vendors by ensuring that only authorized LLMs can execute on target platforms. AttestLLM leverages an algorithm/software/hardware co-design approach to embed robust watermarking signatures onto the activation distributions of LLM building blocks. It also optimizes the attestation protocol within the Trusted Execution Environment (TEE), providing efficient verification without compromising inference throughput. Extensive proof-of-concept evaluations on LLMs from Llama, Qwen, and Phi families for on-device use cases demonstrate AttestLLM's attestation reliability, fidelity, and efficiency. Furthermore, AttestLLM enforces model legitimacy and exhibits resilience against model replacement and forgery attacks.